Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KMTS?
Source: seekingalpha
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMTS
Wall Street analysts forecast KMTS stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.260
Low
27.00
Averages
29.50
High
32.00
Current: 19.260
Low
27.00
Averages
29.50
High
32.00
About KMTS
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
See More
Kestra Medical Technologies Q3 Earnings Exceed Expectations
- Strong Earnings Performance: Kestra Medical Technologies reported a Q3 GAAP EPS of $0.61, beating market expectations by $1.21, which indicates a significant improvement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q3 revenue of $24.55 million, reflecting a year-over-year increase of 62.7% and exceeding expectations by $1.68 million, showcasing strong product demand and market share expansion.
- Increased Market Recognition: Kestra Medical Technologies presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the medical technology sector, which could attract potential investors and partners.
- Historical Performance Data Support: The historical financial data provided by the company indicates a consistent trend of revenue and profit growth, establishing a solid foundation for future business expansion and strengthening its position in the competitive medical technology market.
See More
Kestra Medical Technologies Partners with Biobeat for $5 Million Investment to Enhance Cardiac Recovery Monitoring
- Strategic Collaboration: Kestra Medical Technologies has entered into a strategic collaboration with Biobeat Technologies, involving a $5 million equity investment aimed at integrating Biobeat's cuffless blood pressure monitoring technology into the ASSURE® Wearable Cardioverter Defibrillator, thereby enhancing patient monitoring capabilities and clinical decision support.
- Technological Integration Benefits: Biobeat's FDA-cleared cuffless blood pressure monitoring device provides continuous 24-hour blood pressure data, which will enable Kestra to offer more comprehensive health monitoring for patients during cardiac recovery, particularly in managing hypertensive patients.
- Clinical Research Support: The recent clinical evaluation study of the ASSURE wearable cardioverter defibrillator by Kestra revealed that 72% of participants were hypertensive, underscoring the importance of blood pressure monitoring during cardiac recovery and providing stronger evidence for clinical decision-making.
- Market Outlook: This collaboration not only enhances Kestra's competitiveness in cardiac health monitoring but also demonstrates its strategic vision in promoting at-home patient care and optimizing medical decision-making, which is expected to attract more attention from healthcare providers.
See More
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra Medical Technologies' investor relations website, which will help enhance the company's visibility and transparency among investors.
- Company Background: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra's technology aims to improve patient health outcomes, indicating its strategic significance in the rapidly evolving digital healthcare market.
See More
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Company Background: Focused on transforming patient outcomes in cardiovascular disease, Kestra employs intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, highlighting its innovative capabilities and market potential in the digital healthcare sector.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra's investor relations website, enhancing engagement and transparency with investors.
- Industry Impact: This conference provides Kestra with a platform to showcase its technologies and market strategies, potentially fostering further development in the medical device industry and boosting investor confidence.
See More
Kestra Medical Reports 53% Increase in Q2 Revenue and Raises FY26 Revenue Forecast Once More
Financial Performance: Kestra Medical Technologies reported a 53% increase in revenue for Q2 fiscal 2026, reaching $22.6 million, while gross profit also rose significantly to $11.4 million, leading to an expanded gross margin of 50.6%.
Operating Expenses and Losses: The company faced wider GAAP net losses of $32.8 million, up from $20.6 million in the previous year, with operating expenses increasing to $43.2 million, including non-recurring costs.
Cash Position: As of October 31, 2025, Kestra had $175 million in cash and cash equivalents, not accounting for an additional $148 million from a public offering that closed on December 4, 2025.
Revenue Guidance: Kestra has raised its revenue guidance for fiscal 2026 to $91 million, marking a 52% increase over the previous year's revenue of $59.8 million, following multiple revisions from an initial estimate of $85 million.
See More
Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
See More
Kestra Medical Technologies Q3 Earnings Exceed Expectations
- Strong Earnings Performance: Kestra Medical Technologies reported a Q3 GAAP EPS of $0.61, beating market expectations by $1.21, which indicates a significant improvement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q3 revenue of $24.55 million, reflecting a year-over-year increase of 62.7% and exceeding expectations by $1.68 million, showcasing strong product demand and market share expansion.
- Increased Market Recognition: Kestra Medical Technologies presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the medical technology sector, which could attract potential investors and partners.
- Historical Performance Data Support: The historical financial data provided by the company indicates a consistent trend of revenue and profit growth, establishing a solid foundation for future business expansion and strengthening its position in the competitive medical technology market.
See More
Kestra Medical Technologies Partners with Biobeat for $5 Million Investment to Enhance Cardiac Recovery Monitoring
- Strategic Collaboration: Kestra Medical Technologies has entered into a strategic collaboration with Biobeat Technologies, involving a $5 million equity investment aimed at integrating Biobeat's cuffless blood pressure monitoring technology into the ASSURE® Wearable Cardioverter Defibrillator, thereby enhancing patient monitoring capabilities and clinical decision support.
- Technological Integration Benefits: Biobeat's FDA-cleared cuffless blood pressure monitoring device provides continuous 24-hour blood pressure data, which will enable Kestra to offer more comprehensive health monitoring for patients during cardiac recovery, particularly in managing hypertensive patients.
- Clinical Research Support: The recent clinical evaluation study of the ASSURE wearable cardioverter defibrillator by Kestra revealed that 72% of participants were hypertensive, underscoring the importance of blood pressure monitoring during cardiac recovery and providing stronger evidence for clinical decision-making.
- Market Outlook: This collaboration not only enhances Kestra's competitiveness in cardiac health monitoring but also demonstrates its strategic vision in promoting at-home patient care and optimizing medical decision-making, which is expected to attract more attention from healthcare providers.
See More
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra Medical Technologies' investor relations website, which will help enhance the company's visibility and transparency among investors.
- Company Background: Kestra Medical Technologies focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, demonstrating its innovative potential in the digital healthcare sector.
- Market Positioning: As a commercial-stage wearable medical device company, Kestra's technology aims to improve patient health outcomes, indicating its strategic significance in the rapidly evolving digital healthcare market.
See More
Kestra Medical Technologies to Present at J.P. Morgan Healthcare Conference on January 13
- Conference Schedule: Kestra Medical Technologies is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 at 2:15 p.m. Pacific Time, showcasing its latest advancements in wearable medical devices, which is expected to attract investor and industry attention.
- Company Background: Focused on transforming patient outcomes in cardiovascular disease, Kestra employs intuitive, intelligent, and connected monitoring and therapeutic intervention technologies, highlighting its innovative capabilities and market potential in the digital healthcare sector.
- Investor Relations: Interested parties can access the live webcast and replay of the presentation by visiting Kestra's investor relations website, enhancing engagement and transparency with investors.
- Industry Impact: This conference provides Kestra with a platform to showcase its technologies and market strategies, potentially fostering further development in the medical device industry and boosting investor confidence.
See More
Kestra Medical Reports 53% Increase in Q2 Revenue and Raises FY26 Revenue Forecast Once More
Financial Performance: Kestra Medical Technologies reported a 53% increase in revenue for Q2 fiscal 2026, reaching $22.6 million, while gross profit also rose significantly to $11.4 million, leading to an expanded gross margin of 50.6%.
Operating Expenses and Losses: The company faced wider GAAP net losses of $32.8 million, up from $20.6 million in the previous year, with operating expenses increasing to $43.2 million, including non-recurring costs.
Cash Position: As of October 31, 2025, Kestra had $175 million in cash and cash equivalents, not accounting for an additional $148 million from a public offering that closed on December 4, 2025.
Revenue Guidance: Kestra has raised its revenue guidance for fiscal 2026 to $91 million, marking a 52% increase over the previous year's revenue of $59.8 million, following multiple revisions from an initial estimate of $85 million.
See More
